RxDoctor Payments Data

James Mangrum, MD

Clinical Cardiac Electrophysiology · Charlottesville, VANPI 1215006846

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (38.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by Medtronic at 53.6% of the total. Reporting peaked in 2023 at $14,444 and has fallen 58.9% since, to $5,933 in 2025.

$45,637in general payments, 2019–2025

Across 116 payments — averaging $393.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$24K
  • Cardiofocus, Inc.$20K
  • Abbott$1K
$671,315in research payments, 2019–2025

Across 55 payments — averaging $12,206 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cortex, Inc.$258K
  • Boston Scientific$187K
  • Medtronic$138K
  • Cardiofocus, Inc.$85K
  • Abbott$3K

What the payments were for

  • Consulting fees$14,37531%
  • Speaking & faculty fees$17,63839%
  • Travel & lodging$6,55214%
  • Food & beverage$7,05915%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)85$24,467
Cardiofocus, Inc.20$19,829
Abbott11$1,341

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,637 in reported general payments places this provider in the 70th percentile of 90 clinical cardiac electrophysiology providers in Virginia.

See all clinical cardiac electrophysiology providers in Virginia

Medicare billing

Part B allowed, 2024
$164,664
Medicare patients
870
Services billed
2,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban260$316,591
XareltoRivaroxaban42$61,935
Flecainide Acetate127$7,900
Dofetilide71$7,889
Amiodarone Hcl41$1,295
SotalolSotalol Hcl37$960
Metoprolol Succinate104$820
Metoprolol Tartrate64$568
Diltiazem 24hr Er (Cd)Diltiazem Hcl23$423
Digoxin15$306
Verapamil ErVerapamil Hcl14$293
Furosemide37$207
Losartan Potassium19$189
Atorvastatin Calcium12$146
Lisinopril11$25

Paid to pharmacies, not to this prescriber.

Other clinical cardiac electrophysiology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →